November 2nd, 2026What is it Like to Go From Treating Patients Directly to Running a Company?Dr. Jay Lalezari, CytoDyn’s CEO and CMO, discusses his path from HIV clinician to drug developer.Read more
November 10th, 2026FDA Approves asundexian for Secondary Stroke Risk Reduction FDA approves Bayer’s asundexian (Sunharbo), the first Factor XIa inhibitor, for secondary stroke prevention. Read more
November 10th, 2026Where AI Can Strengthen Clinical Research, and Where Patient Input is More ImportantAI can make clinical trials smarter and faster, but lived patient experience remains irreplaceable in guiding research toward optimal results.Read more
November 9th, 2026Single Partner Platforms: Enhancing the Prescription Journey for ManufacturersSingle-partner platforms can unify manufacturers, prescribers, and patients to eliminate gaps, cut costs, and boost treatment adherence.Read more
November 9th, 2026Effective Methods of Accurately Measuring TumorsIgnite Proteomics measures phosphorylation states to show which proteins are actively driving a tumor—guiding therapy beyond what IHC alone reveals.Read more
November 6th, 2026The US Drug-Pricing Reset: Competing on Net Value As Medicare negotiation, PBM reform, and cash-pay channels converge, winning on auditable net value matters more than cutting list prices.Read more
November 6th, 2026Hims & Hers Partners with Eli Lilly to Sell Obesity Medicines The agreement provides access for prescribed patients to Lilly's obesity medicines self-pay pricing starting at $149 per month without leaving the platform.Read more
November 6th, 2026How Changes in a Tumor Have a Significant Impact on Treatment OptionsWhen tumors shift, old treatments stop working. Dr. Brian Corgiat explains why real-time tumor profiling is critical to effective therapy.Read more